Navigation Links
Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
Date:5/14/2009

FREMONT, Calif., May 14 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "siRNA Therapeutics for Prevention of Ocular and Inner Ear Sensory Cells Death," at the DxRx Summit: Nucleic Acid Diagnostics & Therapeutics. The event was held May 12-13, 2009 in Boston, MA.

Dr. Feinstein presented data demonstrating that synthetic, chemically-modified 19-bp siRNAs, including PF 04523655 currently being studied by partners Pfizer and Quark in patients with diabetic macular edema (DME) and age-related macular degeneration (AMD), enter cells in the retina of the eye and exert their therapeutic effects while avoiding non-specific activation of the toll-like receptor 3 (TLR3) - the effect reported for other synthetic siRNAs. Similar data for QPI-1007, Quark's proprietary siRNA composition, were also reported. QPI-1007 was demonstrated to confer effective ocular neuroprotection and is currently in late-stage IND-enabling studies.

In addition to studies in the eye, Dr. Feinstein also reported results demonstrating effective delivery of synthetic siRNAs to the inner ear, which resulted in protection of hearing epithelium from ototoxic and noise-induced damage. These studies were performed in collaboration with Prof. Jayakrishna Ambati, University of Kentucky College of Medicine, Lexington, KY; Prof. Ann Logan, University of Birmingham, UK; Prof. Adriana Di Polo, University of Montreal; and Prof. Richard Salvi, SUNY University at Buffalo.

Daniel Zurr, Ph.D., President and Chief Executive Officer, said, "Results from the studies presented at DxRx demonstrate our successful track record in discovering and advancing industry-leading siRNA product candidates. Our strong position
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
2. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
5. MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
7. Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention
8. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
9. Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
10. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
11. Vion Pharmaceuticals Reports 2009 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Operation Rescue Launches Opposition to Gov. Sebelius' Confirmation as HHS Secretary 2Health News:Operation Rescue Launches Opposition to Gov. Sebelius' Confirmation as HHS Secretary 3Health News:Latinos Manage Diabetes With Help From the Community 2Health News:Latinos Manage Diabetes With Help From the Community 3Health News:AIDS care physicians make recommendations to Obama 2Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 2Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 3Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 4Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 5Health News:New Jersey to Launch New Statewide Effort to Promote Childhood Obesity Prevention 2Health News:New Jersey to Launch New Statewide Effort to Promote Childhood Obesity Prevention 3Health News:New Jersey to Launch New Statewide Effort to Promote Childhood Obesity Prevention 4Health News:Kathleen Sebelius Ready to Lead Healthcare Reform in 2009 2
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Exponent Reports Second Quarter 2009 Results 52462 1Exponent Reports Second Quarter 2009 Results 52462 2Exponent Reports Second Quarter 2009 Results 52462 3Exponent Reports Second Quarter 2009 Results 52462 4Exponent Reports Second Quarter 2009 Results 52462 5Exponent Reports Second Quarter 2009 Results 52462 6Exponent Reports Second Quarter 2009 Results 52462 7Exponent Reports Second Quarter 2009 Results 52462 8Exponent Reports Second Quarter 2009 Results 52462 9Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 1Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 2Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 3Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 4Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 5Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 1Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 2Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 3Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 4Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 5Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 6Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 7Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 8Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 9Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 10Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 11Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 12Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 13Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 14Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 15Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 16Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 17